Semaglutide Treatment + Sitagliptin 100mg
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Liver Transplant; Complications
Conditions
Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD
Trial Timeline
Oct 26, 2022 → Dec 1, 2024
NCT ID
NCT05195944About Semaglutide Treatment + Sitagliptin 100mg
Semaglutide Treatment + Sitagliptin 100mg is a approved stage product being developed by Novo Nordisk for Liver Transplant; Complications. The current trial status is unknown. This product is registered under clinical trial identifier NCT05195944. Target conditions include Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis.
What happened to similar drugs?
20 of 20 similar drugs in Liver Transplant; Complications were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05195944 | Approved | UNKNOWN |
Competing Products
20 competing products in Liver Transplant; Complications